Benign prostatic hyperplasia: clinical treatment can complicate cataract surgery

• Main Authors: Fernando Facio, Renata Kashiwabuschi, Yutaro Nishi, Ricardo Leao, Peter Mcdonnell, Arthur Burnett
• Format: Article
• Language: English
• Published: Sociedade Brasileira de Urologia 2010-10-01
• Series: International Brazilian Journal of Urology
• Subjects: benign prostatic hyperplasia; alpha-blocker; floppy iris syndrome; cataract complication; tamsulosin
• Online Access: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382010000500006

PURPOSE: To investigate the effects of alpha-1 adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia (BPH) regarding potential risks of complications in the setting of cataract surgery. AIM: To address recommendations, optimal control therapy, voiding symptoms and safety within the setting of cataract surgery. MATERIALS AND METHODS: A comprehensive literature review was performed using MEDLINE with MeSH terms and keywords "benign prostatic hyperplasia", "intraoperative floppy iris syndrome", "adrenergic alpha-antagonist" and "cataract surgery". In addition, reference lists from identified publications were reviewed to identify reports and studies of interest from 2001 to 2009. RESULTS: The first report of intraoperative floppy iris syndrome (IFIS) was observed during cataract surgery in patients taking systemic alpha-1 AR antagonists in 2005. It has been most commonly seen related to use of tamsulosin. Changes of medication and washout periods of up to 2 weeks have been attempted to reduce the risk of complications in the setting of cataract surgery. CONCLUSION: Patients under clinical treatment for BPH should be informed about potential risks of this drug class so that it can be discuss with their healthcare providers, in particular urologist and ophthalmologist, prior to cataract surgery.